Menu

Close

Stories & News

Resources

Stay Informed

Stay Informed

April 29, 2025

Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance

News

April 26, 2025

Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer News

April 24, 2025

Pfizer Announces 2025 Shareholder Meeting Preliminary Results News

April 23, 2025

Pfizer Declares Second-Quarter 2025 Dividend News

April 23, 2025

Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting News

April 16, 2025

ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease News

April 14, 2025

Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron News

April 10, 2025

Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24 News

April 1, 2025

European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease News

March 18, 2025

Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts News

February 13, 2025

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial News

February 24, 2025

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference News

February 13, 2025

Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer News

February 12, 2025

U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma News

February 10, 2025

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC) News

February 4, 2025

Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance News

February 3, 2025

Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial News

January 28, 2025

Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium News

January 25, 2025

Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer News

January 10, 2025

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer News

January 6, 2025

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

December 20, 2024

U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer News

December 19, 2024

Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts News

December 17, 2024

Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance News

December 12, 2024

Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer News

December 12, 2024

Pfizer Declares First-Quarter 2025 Dividend News

December 10, 2024

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium News

December 10, 2024

Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance News

December 5, 2024

Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS News

November 20, 2024

European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors News

November 20, 2024

Pfizer Announces New Chief Scientific Officer and President, Research & Development News

November 14, 2024

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

November 4, 2024

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

October 29, 2024

Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance News

October 23, 2024

Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older News

October 22, 2024

U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease News

October 15, 2024

Tim Buckley Elected to Pfizer’s Board of Directors News

October 11, 2024

U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors News

October 10, 2024

Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial News

October 9, 2024

Pfizer Declares Fourth-Quarter 2024 Dividend News

October 8, 2024

Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024 News

September 25, 2024

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets News

September 20, 2024

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union News

September 17, 2024

Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts News

September 14, 2024

Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer News

September 14, 2024

Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia News

September 11, 2024

Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024 News

September 3, 2024

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate News

August 28, 2024

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

August 27, 2024

Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare News

August 22, 2024

Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine News

August 16, 2024

Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age News

August 12, 2024

Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults News

July 30, 2024

Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance News

July 25, 2024

European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B News

July 24, 2024

Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate News

July 17, 2024

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion News

July 11, 2024

Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron News

July 9, 2024

Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development News

July 1, 2024

Cyrus Taraporevala Elected to Pfizer’s Board of Directors News

June 27, 2024

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union News

June 26, 2024

Pfizer Declares Third-Quarter 2024 Dividend News

June 18, 2024

Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts News

June 14, 2024

ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma News

June 12, 2024

Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy News

June 3, 2024

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference News

June 1, 2024

Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL) News

June 1, 2024

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma News

May 31, 2024

Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression News

May 23, 2024

Malawi Ministry of Health, bioMérieux, and Pfizer Form Country’s First Multisectoral Collaboration to Help Address Antimicrobial Resistance News

May 16, 2024

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) News

May 6, 2024

Pfizer Announces New Chief Strategy and Innovation Officer News

May 1, 2024

Pfizer Reports First-Quarter 2024 Results News

April 29, 2024

Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting News

April 29, 2024

FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer News

April 26, 2024

U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B News

April 25, 2024

Pfizer Announces 2024 Shareholder Meeting Preliminary Results News

April 24, 2024

Pfizer Declares Second-Quarter 2024 Dividend News

April 22, 2024

European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options News

April 11, 2024

Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25 News

April 9, 2024

Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease News

March 13, 2024

European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease News

March 12, 2024

Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL) News

February 29, 2024

Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth News

February 29, 2024

Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO ® for RSV in Older Adults News

February 19, 2024

European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis News

February 12, 2024

UT Southwestern collaborates with Pfizer to develop improved RNA Delivery Technologies News

February 5, 2024

Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities News

January 30, 2024

Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance News

January 26, 2024

European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer News

January 10, 2024

Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation News

January 9, 2024

TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer News

January 8, 2024

European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer News

January 2, 2024

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference News

December 19, 2023

Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts News

December 15, 2023

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer News

December 14, 2023

Pfizer Completes Acquisition of Seagen News

December 14, 2023

Pfizer Declares First-Quarter 2024 Dividend News

December 13, 2023

Pfizer Provides Full-Year 2024 Guidance News

December 12, 2023

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen News

December 11, 2023

FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B News

December 9, 2023

Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B News

December 8, 2023

European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma News

December 1, 2023

Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity News

November 21, 2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

November 17, 2023

Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting News

November 2, 2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

November 2, 2023

Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting News

October 31, 2023

Pfizer Reports Third-Quarter 2023 Results News

October 26, 2023

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19 News

October 20, 2023

FDA Approves PENBRAYA™,the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents News

October 13, 2023

U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC) News

October 13, 2023

Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance News

October 12, 2023

U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer News

October 5, 2023

Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases News

October 4, 2023

Pfizer Declares Fourth-Quarter 2023 Dividend News

September 22, 2023

Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV News

September 20, 2023

Pfizer Quarterly Corporate Performance – Third Quarter 2023 News

September 19, 2023

European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata News

September 19, 2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

September 18, 2023

Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts News

September 12, 2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

September 11, 2023

Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine News

September 5, 2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

August 30, 2023

Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences News

August 30, 2023

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union News

August 24, 2023

European Commission Approves Pfizer’s ABRYSVO™ to Help Protect Infants through Maternal Immunization and Older Adults from RSV News

August 21, 2023

U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age News

August 14, 2023

Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma News

August 1, 2023

Pfizer Reports Second-Quarter 2023 Results News

July 27, 2023

Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy News

July 21, 2023

Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility News

July 19, 2023

Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS)Maternal Vaccine Candidate News

July 18, 2023

Flagship Pioneering and Pfizer Partner to Accelerate Development of Innovative Medicines Targeting Unmet Needs News

June 28, 2023

FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency News

June 27, 2023

FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec News

June 26, 2023

FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata News

June 26, 2023

Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus News

June 22, 2023

Pfizer Declares Third-Quarter 2023 Dividend News

June 20, 2023

Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts News

June 20, 2023

Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval News

June 6, 2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

June 1, 2023

Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options News

May 31, 2023

U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults News

May 30, 2023

Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial News

May 25, 2023

Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19 News

May 25, 2023

Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting News

May 18, 2023

FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization News

May 16, 2023

Pfizer Prices $31,000,000,000 Debt Offering News

May 15, 2023

Pfizer Announces Proposed Notes Offering News

May 4, 2023

Pfizer Invites Retail Shareholders to a General Q&A Session News

May 2, 2023

Pfizer Reports First-Quarter 2023 Results News

April 27, 2023

U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children News

April 26, 2023

Pfizer Declares Second-Quarter 2023 Dividend News

April 13, 2023

Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27 News

April 4, 2023

FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI News

March 21, 2023

Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts News

March 16, 2023

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™ News

March 13, 2023

Pfizer Invests $43 Billion to Battle Cancer News

March 10, 2023

Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval News

February 28, 2023

Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults News

February 27, 2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

February 22, 2023

Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance News

February 21, 2023

U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for PriorityReview News

February 16, 2023

Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study News

February 16, 2023

Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults News

February 10, 2023

FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib) News

February 9, 2023

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference News

January 31, 2023

Pfizer Reports Record Full-Year 2022 Results and Provides Full-Year 2023 Financial Guidance News

January 17, 2023

Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries News

January 6, 2023

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children News

January 3, 2023

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference News

December 29, 2022

Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate News

December 28, 2022

U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents News

December 21, 2022

Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis News

December 20, 2022

Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts News

December 10, 2022

Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial News

December 9, 2022

Pfizer Declares First-Quarter 2023 Dividend News

December 8, 2022

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years News

December 7, 2022

U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults News

December 6, 2022

Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease News

December 1, 2022

Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day News

December 1, 2022

Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate News

November 28, 2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

November 18, 2022

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages News

November 16, 2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

November 16, 2022

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5-11 Years of Age in European Union News

November 4, 2022

Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine News

November 3, 2022

Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma News

November 1, 2022

Pfizer Reports Strong Third-Quarter 2022 Results and Raises 2022 Outlook News

November 1, 2022

Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate News

October 18, 2022

Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022 News

October 13, 2022

Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older News

October 12, 2022

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age News

October 5, 2022

Pfizer Completes Acquisition of Global Blood Therapeutics News

October 4, 2022

Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial News

October 3, 2022

Pfizer Completes Acquisition of Biohaven Pharmaceuticals News

September 26, 2022

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age News

September 22, 2022

Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries News

September 22, 2022

Pfizer Declares Fourth-Quarter 2022 Dividend News

September 20, 2022

Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts News

September 19, 2022

Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union News

September 15, 2022

Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents News

September 14, 2022

Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022 News

September 14, 2022

Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine News

August 31, 2022

Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older News

August 26, 2022

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine News

August 25, 2022

Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate News

August 8, 2022

Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology News

August 8, 2022

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15 News

August 5, 2022

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis News

July 28, 2022

Pfizer Reports Second-Quarter 2022 Results News

July 19, 2022

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 Adapted Bivalent Vaccine Candidate News

July 8, 2022

Pfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children 6 Months to less than 5 Years with COMIRNATY® News

July 8, 2022

Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age News

June 30, 2022

Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™ News

June 30, 2022

Pfizer Announces Commitment to Accelerate Climate Action and Achieve Net-Zero Standard by 2040 News

June 29, 2022

Pfizer Quarterly Corporate Performance – Second Quarter 2022 News

June 29, 2022

Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine News

June 28, 2022

Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus News

June 25, 2022

COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron News

June 24, 2022

Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts News

June 23, 2022

Pfizer Declares Third-Quarter 2022 Dividend News

June 20, 2022

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15 News

June 17, 2022

Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age News

June 17, 2022

Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain News

June 15, 2022

Pfizer and BioNTech Provide Update on Rolling Submission to European Medicines Agency for a Potential Variant-Adapted Vaccine News

June 14, 2022

Pfizer Reports Additional Data on PAXLOVID™Supporting Upcoming New Drug Application Submission to U.S. FDA News

June 9, 2022

Pfizer Completes Acquisition of ReViral News

June 9, 2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

June 8, 2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

June 6, 2022

Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S. News

June 4, 2022

Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer News

June 1, 2022

Pfizer Provides Update on Ownership Interest in Haleon News

May 31, 2022

Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability News

May 26, 2022

Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH) News

May 25, 2022

Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries News

May 25, 2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

May 24, 2022

Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis News

May 23, 2022

Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose News

May 17, 2022

Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age News

May 10, 2022

Pfizer to Acquire Biohaven Pharmaceuticals News

May 3, 2022

Pfizer Reports First-Quarter 2022 Results News

April 28, 2022

Pfizer Declares Second-Quarter 2022 Dividend News

April 27, 2022

Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine News

April 27, 2022

Join Pfizer's 2022 Annual Meeting of Shareholders News

April 26, 2022

Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate News

April 19, 2022

Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28 News

April 14, 2022

Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age News

April 11, 2022

Pfizer Names David M. Denton Chief Financial Officer News

April 7, 2022

Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates News

March 29, 2022

Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential News

March 29, 2022

Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older News

March 24, 2022

Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults News

March 23, 2022

Join Pfizer's First Quarter 2022 Corporate Performance on 5/3 News

March 23, 2022

Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients News

March 22, 2022

Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries News

March 22, 2022

Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts News

March 9, 2022

Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants News

March 9, 2022

Join Barclays Global Healthcare Conference on 3/15 News

March 8, 2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

March 2, 2022

Cowen 42nd Annual Health Care Conference News

March 2, 2022

Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women News

February 15, 2022

Pfizer and OPKO’s Once-Weekly NGENLA™(somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency News

February 15, 2022

European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults News

February 11, 2022

Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age News

February 9, 2022

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference News

February 8, 2022

Pfizer Reports Fourth-Quarter 2021 Results News

February 1, 2022

Pfizer Announces New Chief Development Officer News

February 1, 2022

Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA News

January 28, 2022

European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer News

January 27, 2022

Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment News

January 14, 2022

U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis News

January 10, 2022

Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics News

January 10, 2022

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases News

January 5, 2022

Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine News

January 4, 2022

Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19 News

January 3, 2022

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older News

December 22, 2021

Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment News

December 16, 2021

EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate News

December 14, 2021

U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis News

December 14, 2021

Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death News

December 13, 2021

Pfizer to Acquire Arena Pharmaceuticals News

December 10, 2021

Pfizer Declares First-Quarter 2022 Dividend News

December 10, 2021

European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis News

December 9, 2021

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older News

December 8, 2021

Pfizer and BioNTech Provide Update on Omicron Variant News

December 7, 2021

Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate News

November 24, 2021

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference News

November 22, 2021

Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age News

November 19, 2021

Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older News

November 18, 2021

Pfizer Completes Acquisition of Trillium Therapeutics News

November 18, 2021

Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis News

November 10, 2021

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference News

October 29, 2021

Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years News

October 28, 2021

Pfizer and BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs News

October 26, 2021

FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech Covid-19 Vaccine in Children 5 to <12 Years News

October 21, 2021

Pfizer and Biontech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of their COVID-19 Vaccine News

October 20, 2021

Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer's PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adults News

September 27, 2021

Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program News

September 23, 2021

Pfizer Invites Public to View and Listen to Webcast of Pfizer November 2 Conference Call with Analysts News

September 22, 2021

Pfizer and Biontech Receive First U.S. FDA Emergency Use Authorization of a Covid-19 Vaccine Booster News

September 10, 2021

Pfizer Post Images copy News

August 26, 2021

Pfizer Announces New Chief Business Innovation Officer News

August 23, 2021

Pfizer-Biontech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older News

July 28, 2021

Pfizer Reports Second-Quarter 2021 Results News

Back

Page 1 of 42

Next

Corporate Pfizer Newsroom

Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.
 


Copyright © 2002 – 2025 Pfizer Investor Insights All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries. This website contains certain information about Pfizer, but may not contain all information that is material to Pfizer.